Canada -
français -
Health Canada
esbriet capsule
hoffmann-la roche limited - pirfénidone - capsule - 267mg - pirfénidone 267mg - antifibrotic agents
Canada -
français -
Health Canada
jamp pirfenidone comprimé
jamp pharma corporation - pirfénidone - comprimé - 267mg - pirfénidone 267mg - antifibrotic agents
Canada -
français -
Health Canada
jamp pirfenidone comprimé
jamp pharma corporation - pirfénidone - comprimé - 801mg - pirfénidone 801mg - antifibrotic agents
Canada -
français -
Health Canada
pms-pirfenidone comprimé
pharmascience inc - pirfénidone - comprimé - 267mg - pirfénidone 267mg
Canada -
français -
Health Canada
pms-pirfenidone comprimé
pharmascience inc - pirfénidone - comprimé - 801mg - pirfénidone 801mg
Canada -
français -
Health Canada
sandoz pirfenidone tablets comprimé
sandoz canada incorporated - pirfénidone - comprimé - 267mg - pirfénidone 267mg - antifibrotic agents
Canada -
français -
Health Canada
sandoz pirfenidone tablets comprimé
sandoz canada incorporated - pirfénidone - comprimé - 801mg - pirfénidone 801mg - antifibrotic agents
Canada -
français -
Health Canada
sandoz pirfenidone capsules
sandoz canada incorporated - pirfénidone - capsule - 267mg - pirfénidone 267mg - antifibrotic agents
Canada -
français -
Health Canada
jamp pirfenidone capsule
jamp pharma corporation - pirfénidone - capsule - 267mg - pirfénidone 267mg - antifibrotic agents
Union européenne -
français -
EMA (European Medicines Agency)
teysuno
nordic group b.v. - tegafur, gimeracil, l'otéracil - néoplasmes stomacaux - agents antinéoplasiques - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.